Compare LUNG & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LUNG | COCH |
|---|---|---|
| Founded | 1995 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Industrial Specialties | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.9M | 49.7M |
| IPO Year | 2020 | N/A |
| Metric | LUNG | COCH |
|---|---|---|
| Price | $1.35 | $0.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $5.38 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 349.1K | 117.8K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $90,497,000.00 | N/A |
| Revenue This Year | $2.48 | $1.58 |
| Revenue Next Year | $18.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.01 | N/A |
| 52 Week Low | $1.13 | $0.36 |
| 52 Week High | $3.88 | $1.89 |
| Indicator | LUNG | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 46.88 | 46.14 |
| Support Level | $1.20 | $0.64 |
| Resistance Level | $1.45 | $0.74 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 32.14 | 37.82 |
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.